Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone- refractory prostate cancer: A Southwest Oncology Group report

Maha Hussain*, Michael Wolf, Ernest Marshall, E. David Crawford, Mario Eisenberger

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

123 Scopus citations

Fingerprint Dive into the research topics of 'Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone- refractory prostate cancer: A Southwest Oncology Group report'. Together they form a unique fingerprint.

Medicine & Life Sciences